Cellegy Cellegesic Re-Analysis Of Anal Fissure Pain Relief Data Slated For Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA takes Cellegesic data analyses on pain reduction and fissure healing to cardio-renal advisory committee following protracted review.
You may also be interested in...
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
FDA Antihypertensive Draft Class Labeling To Be Reviewed By Cardio-Renal Committee
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
Cellegy’s Headache: FDA Says Analgesic Use May Have Skewed Cellegesic Efficacy Results
FDA advisory committee preview documents question whether concomitant acetaminophen use in trials of the nitroglycerin ointment could be responsible for a small reduction in anal fissure pain.